Harrison.ai raises $112M Series C to expand AI-powered medical diagnostics and U.S. operations

Company name: Harrison.ai
Location: Haymarket, Australia
Industry: Health Tech

Funding details:

• Amount: $112M (Series C round, bringing total funding to $240M)
• Investors:
  • Lead: Aware Super, ECP, Horizons Ventures
  • New Participants: Australia’s National Reconstruction Fund Corporation (NRFC), Ord Minnett, Wollemi Capital Group
  • Existing Investors: Blackbird Ventures, Alpha JWC Ventures

Purpose of investment:

• Expand U.S. operations and establish a North American presence in Boston
• Grow customer base and accelerate commercialization globally

Leadership:

• CEO & Co-founder: Dr. Aengus Tran

Product:
Harrison.ai develops AI-powered diagnostic support and workflow solutions for radiology (Annalise.ai) and pathology (Franklin.ai), assisting clinicians in detecting and diagnosing cancer and other critical illnesses earlier.

Key features:

• AI-driven radiology and pathology solutions: Enhances clinical workflows by analyzing CT scans, X-rays, and pathology slides to identify medical conditions faster and with greater accuracy.
• Improved patient outcomes: Supports healthcare providers in making more informed treatment decisions by identifying critical illnesses at an early stage.
• Global partnerships: Works with hospitals and private clinics across APAC, EMEA, the UK, and the U.S. to implement AI-driven diagnostic solutions.

Regulatory approvals and impact:

• 12 FDA clearances received for AI diagnostic models.
• CT Brain algorithm is designated as an FDA Breakthrough Device and qualifies for Medicare reimbursement through the New Technology Add-on Payment (NTAP) program.

Future plans:
With this funding, Harrison.ai will scale its AI-driven healthcare solutions, deepen its presence in the U.S. market, and expand its clinical partnerships to drive adoption of AI-powered medical diagnostics worldwide.